Purchase Order 75N95024P00612
Award Date
9/16/24
Potential Completion Date
9/30/24
Potential Value
$24K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
NAICS Category
325199 - All Other Basic Organic Chemical Manufacturing
PSC Category
6505 - Drugs And Biologicals
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Coralville, IA 52241, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a Firm Fixed Price purchase order to Integrated DNA Technologies, Inc. (IDT) for the custom synthesis of 9 antisense oligonucleotides (ASOs) in support of a liver toxicity study. The order has a potential value of $24,912.77 and a completion date of August 24, 2023. IDT is a manufacturer of nucleic acid products that has previously provided a range of goods and...
This is a firm-fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH), to Integrated DNA Technologies, Inc. (IDT) for the supply of twelve (12) antisense oligonucleotides (ASOs) for an in-vivo neurotoxicity study. The contract has a ceiling value of $11,940.00 and a period of performance through March 26, 2026. This purchase order does not have a set-aside designation. IDT is a leading...
This is a firm fixed-price purchase order awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences to Integrated DNA Technologies, Inc. (IDT), a manufacturer of nucleic acid products, for the custom synthesis of 1,536 antisense oligonucleotides in support of the SARS-CoV2 project. The potential value of this contract is $102,912.00. IDT has previously received awards from federal agencies such as the NIH, Centers for Disease Control and...
This federal contract award was issued by the National Institutes of Health (NIH) Clinical Center to Integrated DNA Technologies, Inc. (IDT), a leading provider of specialized nucleic acid products and services to the U.S. federal government. The $95,173.74 firm-fixed-price purchase order does not have a set-aside designation. IDT has provided a diverse array of products and services through its federal contract awards, including custom DNA oligonucleotides, antisense oligonucleotides for...
This is a firm-fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Integrated DNA Technologies, Inc. (IDT), a leading provider of specialized nucleic acid products and services to the U.S. federal government. The $5,040 contract does not have a set-aside designation. Under this contract, IDT is supplying custom DNA and RNA oligonucleotides, gene fragments, next-generation sequencing products, primers, probes, and other reagents to support a...
The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a firm fixed price purchase order to Integrated DNA Technologies, Inc. (IDT) for the custom synthesis of 1,536 antisense oligonucleotides targeting the CHCHD10 gene. The $102,915.50 contract has an August 29, 2022 completion date and does not have a set-aside designation. IDT is a manufacturer of nucleic acid products that has previously supported...
This non-competitive contract award from the National Institutes of Health's National Center for Advancing Translational Sciences to Integrated DNA Technologies, Inc. is for $20,026.50 to provide custom synthesis of nine antisense oligonucleotides for a neurotoxicology study. Per the solicitation, IDT will synthesize the oligos using proprietary machines and deliver the highest accuracy in sequence. They will also offer design support and expertise. The period of performance is August 7-21,...
This is a firm-fixed-price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to Integrated DNA Technologies, Inc. (IDT), a leading provider of specialized nucleic acid products and services to the U.S. federal government. The $4,480 contract, without a set-aside designation, is for the delivery of various products including custom DNA and RNA oligonucleotides, gene fragments, next-generation sequencing products, primers, probes, and other reagents for biomedical...
This is a firm-fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Integrated DNA Technologies, Inc. (IDT), a leading provider of specialized nucleic acid products and services to the U.S. federal government. The $5,040 contract is for the delivery of various nucleic acid-based products and services, including custom DNA and RNA oligonucleotides, gene fragments, next-generation sequencing products, primers, probes, and other reagents for...
This is a firm-fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Integrated DNA Technologies, Inc. (IDT) for the provision of biological reagents. The contract has a ceiling value of $26,621.50 and a performance period ending on August 31, 2025. IDT is a leading provider of specialized nucleic acid products and services to the federal government, including custom...